【产品介绍】：

中文别名 Danaparoid 英文别名 Danaparoid CAS号 308068-55-5 SMILES Not Available Inchi InchiKey 分子式 Formula Not Available 分子量 Molecular Weight Not Available 闪点 FP NA 熔点 Melting point NA 沸点 Boiling point NA Polarizability极化度 密度 Density NA 蒸汽压 Vapor Pressure 溶解度Solubility 性状 NA 储藏条件 Storage conditions Danaparoid使用注意事项：1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害。3.取样品的移液枪头需及时更换，必要时为避免交叉污染尽可能选择滤芯吸头。4.称量药品时选用称量纸，并无风处取药和称量以免扬撒，试剂的容器使用前务必确保干净，并消毒。5.取药品时尽量采用多个药勺分别使用，使用后清洗干净。6.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染。大规格定制：定制产品请将信息发送至sales@bio-fount.com。Experimental considerations: 1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment. 2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution. 产品说明 Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans2. The active constituents are heparan, dermatan andChondroitin sulfate4, and they are isolated from the porcine intestinal mucosaLabel. Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa). It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients. Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and prevention of post-operative deep venous thrombosis (DVT). While it was initially approved by the FDA as Orgaran?, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. The use of Orgaran? was discontinued in the United States however it is available in several other countries including European countries and Japan. Danaparoid sodium is the common salt form in therapeutic preparations and is typically administered subcutaneously. IntroductionFor use as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. Application1Deep Vein Thrombosis caused by Major Abdominal SurgeryDeep Vein Thrombosis caused by Orthopedic SurgeryDeep Vein Thrombosis caused by Thoracic SurgeryHeparin Induced Thrombocytopenia (HIT)Non-hemorrhagic stroke Application2 Application3 警示图 危险性 危险性警示 warning 安全声明 安全防护 备注 实验过程中防止吸入、食如，做好安全防护 对不起，暂无产品评价！